Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF

被引：0
|
作者：
Pozniak, A. [1 ]
Maggiolo, F. [2 ]
Podzamczer, D. [3 ]
Yazdanpanah, Y. [4 ]
Gupta, S. [5 ]
Esser, S. [6 ]
Mounzer, K. [7 ]
Grossberg, R. [8 ]
Post, F. [9 ]
Huang, H. [10 ]
Acosta, R. [10 ]
Baeten, J. [10 ]
Hindman, J. [10 ]
Martin, H. [10 ]
Orkin, C. [11 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy
[3] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain
[4] Hop Bichat Claude Bernard, AP HP, Paris, France
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Univ Hosp Essen, Essen, Germany
[7] Univ Penn, Philadelphia FIGHT Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
[9] Kings Coll Hosp NHS Fdn Trust, Kings Coll Hosp, London, England
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[11] Queen Mary Univ London, London, England
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/68
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [1] Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF
    Orkin, C.
    Antinori, A.
    Rockstroh, J.
    Guillen, S. Moreno
    Martorell, C.
    Molina, J.
    Lazzarin, A.
    Maggiolo, F.
    Yazdanpanah, Y.
    Andreatta, K.
    Huang, H.
    Hindman, J.
    Martin, H.
    Baeten, J.
    Pozniak, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 88 - 89
  • [2] Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo
    Acosta, T. Parraga
    Osborn, Z.
    Lee, J. C.
    Haubrich, R. H.
    McNicholl, I.
    McKinnon, J. E.
    HIV MEDICINE, 2019, 20 : 88 - 88
  • [3] Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years
    Daar, Eric
    Orkin, Chloe
    Sax, Paul
    Koenig, Ellen
    Clarke, Amanda
    Baumgarten, Axel
    Brinson, Cynthia
    Huang, Hailin
    Martin, Hal
    HIV MEDICINE, 2022, 23 : 12 - 12
  • [4] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results
    Podzamczer, D.
    Stellbrink, H-J
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    SenGupta, D.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 18 - 18
  • [5] A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48
    Gallant, J.
    Lazzarin, A.
    Mills, A.
    Orkin, C.
    Podzamczer, D.
    Tebas, P.
    Girard, P-M
    Brar, I.
    Daar, E.
    Wohl, D.
    Rockstroh, J.
    Wei, X.
    White, K.
    Martin, H.
    Quirk, E.
    Cheng, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 103 - 104
  • [6] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
    Acosta, Rima K.
    Willkom, Madeleine
    Andreatta, Kristen
    Liu, Hui
    Martin, Ross
    Parvangada, Aiyappa
    Martin, Hal
    Collins, Sean
    White, Kirsten L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
  • [7] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results
    Podzamczer, D.
    Stellbrink, H.
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    Cheng, A.
    SenGupta, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [8] Patient-reported outcomes among adults living with HIV-1 who were randomly allocated to B/F/TAF versus DTG/ABC/3TC in two Phase 3 controlled clinical trials over 48 weeks
    Wohl, D.
    Clarke, A.
    Maggiolo, F.
    Garner, W.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 63 - 63
  • [9] RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
    Degroote, Sophie
    Blomme, Evy
    Delesie, Liesbeth
    Vandekerckhove, Linos
    De Scheerder, Marie-Angelique
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 65 - 65
  • [10] Risk of occult HBV infection reactivation in patients receiving ABC/3TC/DTG or FTC/TAF/EVG/c
    Morras, I.
    Gutierrez, A.
    Mills, P.
    Moreno-Torres, V.
    De La Fuente, S.
    Folguera, C.
    Angel-Moreno, A.
    Diaz-de Santiago, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345